Upside down image of a man on a couch.

After FLT3m+ AML Has
Turned Your Life Upside Down

Turn Here For Help

XOSPATA is the only FDA-approved targeted therapy for people with FLT3m+ AML when the disease has come back or has not improved after previous treatment

AML=acute myeloid leukemia; FDA=Food and Drug Administration; FLT3=FMS-like tyrosine kinase 3; m+=mutation-positive.

Man and woman icon.

XOSPATA May Help People Live Longer

XOSPATA was studied in people with FLT3m+ AML when the disease had come back or had not improved after previous treatment. The study compared overall survival in people who had taken XOSPATA vs those who received chemotherapy. In the study, the median overall survival for people who took XOSPATA was 9 months vs 6 months with chemotherapy.

Overall survival: The length of time during the study of XOSPATA that people stayed alive beyond the start of treatment.
Median: The middle value in a set of numbers, not the average.
Holding hands icon.

XOSPATA Support SolutionsSM Is Here to Help

XOSPATA Support Solutions can help provide you or your loved one with information about financial assistance programs.

Select Safety Information
What is the most important information I should know about XOSPATA?

XOSPATA may cause serious side effects including Differentiation Syndrome. Differentiation Syndrome is a condition that affects your blood cells and may be life-threatening or lead to death if not treated. Differentiation Syndrome can happen as early as 1 day after starting XOSPATA and during the first 3 months of treatment. Call your healthcare provider or go to the nearest hospital emergency room right away if you develop any of the following symptoms of differentiation syndrome while taking XOSPATA: fever, cough, dizziness or lightheadedness, rapid weight gain, trouble breathing, swelling of your arms or legs, rash, decreased urination. If you develop any of these symptoms of differentiation syndrome, your healthcare provider may treat you with a corticosteroid medicine and may monitor you in the hospital.

Patient Stories: Living with AML

Watch the story of one patient’s journey with AML.


The patient featured in this video is taking or has taken XOSPATA. The patient and caregiver were compensated by Astellas to share their story.

Results may vary. Talk with your doctor about what this may mean for you.